hepatorenal syndrome

Summary

Summary: Functional KIDNEY FAILURE in patients with liver disease, usually LIVER CIRRHOSIS or portal hypertension (HYPERTENSION, PORTAL), and in the absence of intrinsic renal disease or kidney abnormality. It is characterized by intense renal vasculature constriction, reduced renal blood flow, OLIGURIA, and sodium retention.

Top Publications

  1. ncbi Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study
    Richard Moreau
    INSERM U 481 et Service d Hépatologie, Hopital Beaujon, Clichy, France
    Gastroenterology 122:923-30. 2002
  2. ncbi MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation
    Carlo Alessandria
    Liver Unit, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain
    Hepatology 41:1282-9. 2005
  3. ncbi Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome
    Sergio Neri
    Department of Internal Medicine and Systemic Diseases, Liver Operative Unit, Catania University Polyclinic, Catania 95123, Italy
    Dig Dis Sci 53:830-5. 2008
  4. ncbi Hepatorenal syndrome
    Pere Gines
    Liver Unit, Hospital Cli nic, Institut d Investigacions Biomèdiques August Pi Sunyer, University of Barcelona School of Medicine, Barcelona, Catalunya, Spain
    Lancet 362:1819-27. 2003
  5. ncbi Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome
    Lise L Gluud
    Department of Internal Medicine, Copenhagen University Hospital Gentofte, Hellerup, Denmark
    Hepatology 51:576-84. 2010
  6. doi Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study
    Marta Martín-Llahí
    Liver Unit, Hospital Clinic, University of Barcelona School of Medicine, Institut d Investigacions Biomédiques August Pi Sunyer IDIBAPS, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, Barcelona, Spain
    Gastroenterology 134:1352-9. 2008
  7. pmc A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome
    Arun J Sanyal
    Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
    Gastroenterology 134:1360-8. 2008
  8. ncbi Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide
    P Angeli
    Department of Clinical and Experimental Medicine, University of Padua, Padova, Italy
    Hepatology 29:1690-7. 1999
  9. ncbi Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study
    Christophe Duvoux
    Service d hépatologie et de gastroentérologie, AP HP, Hopital Henri Mondor, Creteil, France
    Hepatology 36:374-80. 2002
  10. ncbi Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study
    Chantal Halimi
    Service d Hepato Gastroenterologie, Centre Hospitalier de Senlis, Paris, France
    Eur J Gastroenterol Hepatol 14:153-8. 2002

Detail Information

Publications258 found, 100 shown here

  1. ncbi Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study
    Richard Moreau
    INSERM U 481 et Service d Hépatologie, Hopital Beaujon, Clichy, France
    Gastroenterology 122:923-30. 2002
    Type 1 hepatorenal syndrome (HRS) is a severe complication of cirrhosis associated with a short median survival time (<2 weeks). Although the administration of terlipressin improves renal function, its effect on survival is unknown...
  2. ncbi MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation
    Carlo Alessandria
    Liver Unit, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain
    Hepatology 41:1282-9. 2005
    Important progress has been made recently regarding the pathogenesis and treatment of hepatorenal syndrome (HRS). However, scant information exists about factors predicting outcome in patients with cirrhosis and HRS...
  3. ncbi Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome
    Sergio Neri
    Department of Internal Medicine and Systemic Diseases, Liver Operative Unit, Catania University Polyclinic, Catania 95123, Italy
    Dig Dis Sci 53:830-5. 2008
    b>Hepatorenal syndrome (HRS) is a pre-renal-like dysfunction that generally onsets in cirrhotic patients presenting ascites...
  4. ncbi Hepatorenal syndrome
    Pere Gines
    Liver Unit, Hospital Cli nic, Institut d Investigacions Biomèdiques August Pi Sunyer, University of Barcelona School of Medicine, Barcelona, Catalunya, Spain
    Lancet 362:1819-27. 2003
    b>Hepatorenal syndrome (HRS) is a common complication of advanced cirrhosis, characterised by renal failure and major disturbances in circulatory function. Renal failure is caused by intense vasoconstriction of the renal circulation...
  5. ncbi Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome
    Lise L Gluud
    Department of Internal Medicine, Copenhagen University Hospital Gentofte, Hellerup, Denmark
    Hepatology 51:576-84. 2010
    Vasoconstrictor drugs may improve renal function in hepatorenal syndrome (HRS), but the effect on mortality has not been established...
  6. doi Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study
    Marta Martín-Llahí
    Liver Unit, Hospital Clinic, University of Barcelona School of Medicine, Institut d Investigacions Biomédiques August Pi Sunyer IDIBAPS, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, Barcelona, Spain
    Gastroenterology 134:1352-9. 2008
    b>Hepatorenal syndrome is common in patients with advanced cirrhosis and constitutes a major problem in liver transplantation. There is no effective medical treatment for hepatorenal syndrome.
  7. pmc A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome
    Arun J Sanyal
    Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
    Gastroenterology 134:1360-8. 2008
    b>Hepatorenal syndrome (HRS) type 1 is a progressive functional renal failure in subjects with advanced liver disease...
  8. ncbi Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide
    P Angeli
    Department of Clinical and Experimental Medicine, University of Padua, Padova, Italy
    Hepatology 29:1690-7. 1999
    ..inhibitor of the release of endogenous vasodilators together with a vasoconstrictor agent in patients with hepatorenal syndrome (HRS)...
  9. ncbi Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study
    Christophe Duvoux
    Service d hépatologie et de gastroentérologie, AP HP, Hopital Henri Mondor, Creteil, France
    Hepatology 36:374-80. 2002
    ..5 mg/h NA) that did not recur after a dose reduction. In conclusion, NA combined with albumin and furosemide appears effective and safe for the treatment of type 1 HRS...
  10. ncbi Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study
    Chantal Halimi
    Service d Hepato Gastroenterologie, Centre Hospitalier de Senlis, Paris, France
    Eur J Gastroenterol Hepatol 14:153-8. 2002
    b>Hepatorenal syndrome (HRS) is a severe complication of cirrhosis, leading to death in more than 90% of cases in the absence of liver transplantation. Several treatments have been attempted as a bridge to liver transplantation...
  11. ncbi Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis
    Isabelle Colle
    Laboratoire d Hémodynamique Splanchmique et de Biologie Vasculaire, Institut National de la Santé et de la Recherge Médicale, Clinchy, France
    J Gastroenterol Hepatol 17:882-8. 2002
    Terlipressin has been proposed to treat renal failure in patients with type 1 hepatorenal syndrome (HRS)...
  12. doi Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis
    Florence Wong
    Department of Medicine, Toronto General Hospital, University of Toronto, Toronto, Ontario M5G2C4, Canada
    Gut 60:702-9. 2011
    ..Therefore, there is a need for a newer classification to include both functional and structural renal diseases...
  13. ncbi Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial
    S R Mitzner
    Department of Medicine, University of Rostock, Germany
    Liver Transpl 6:277-86. 2000
    In hepatorenal syndrome (HRS), renal insufficiency is often progressive, and the prognosis is extremely poor under standard medical therapy...
  14. ncbi Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation
    Gianni Testino
    Unit of Hepato Gastroenterology Monoblocco 12, S Martino Hospital, Piazzale R Benzi 16132, Genova, Italy
    Hepatogastroenterology 50:1753-5. 2003
    ..Its role in the management of refractory ascites and hepatorenal syndrome still awaits further prospective studies. Type-2 hepatorenal syndrome is a moderate steady renal impairment...
  15. pmc Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group
    Mitra K Nadim
    Department of Medicine, University of Southern California, 1520 San Pablo Street, Suite 4300, Los Angeles, CA 90033, USA
    Crit Care 16:R23. 2012
    ..Since the original publication of the definition and diagnostic criteria for the hepatorenal syndrome (HRS), there have been major advances in our understanding of its pathogenesis...
  16. doi Terlipressin in hepatorenal syndrome: Evidence for present indications
    Harshal Rajekar
    Department of General Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India
    J Gastroenterol Hepatol 26:109-14. 2011
    b>Hepatorenal syndrome (HRS) is the most frequent life threatening complication of advanced liver failure and cirrhosis...
  17. ncbi The Prometheus device for extracorporeal support of combined liver and renal failure
    Kinan Rifai
    Division of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany
    Blood Purif 23:298-302. 2005
    ..Therefore, it is a promising treatment option for patients with hepatorenal syndrome (HRS).
  18. ncbi The use of albumin in all patients with decompensated cirrhosis is not justified
    Benjamin Avidan
    Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel
    Isr Med Assoc J 7:118-20. 2005
  19. ncbi Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome
    Eric Esrailian
    Division of Digestive Diseases, David Geffen School of Medicine at UCLA, USA
    Dig Dis Sci 52:742-8. 2007
    Type 1 hepatorenal syndrome (HRS) can be a rapidly fatal consequence of liver failure. Recent studies have utilized vasoconstrictor therapies to combat splanchnic vasodilatation...
  20. ncbi Hepatorenal syndrome: a proposal for kidney after liver transplantation (KALT)
    Richard Ruiz
    Baylor Regional Transplant Institute, Dallas, TX 75246, USA
    Liver Transpl 13:838-43. 2007
    b>Hepatorenal syndrome (HRS) is a well-recognized complication of end-stage liver disease...
  21. ncbi An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response
    Praveen Sharma
    Department of Gastroenterology, G B Pant Hospital, New Delhi, India
    Am J Gastroenterol 103:1689-97. 2008
    b>Hepatorenal syndrome (HRS) is characterized by functional renal failure in end-stage liver disease. Terlipressin is the drug of choice for treating type 1 HRS (HRS-1). It is expensive and often not readily available...
  22. doi Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense ascites
    Andreas Umgelter
    II Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Ismaninger Str 22, 81675, Munich, Germany
    Intensive Care Med 35:152-6. 2009
    ..To assess the effect of reducing intra-abdominal pressure (IAP) by paracentesis on renal resistive index (RI), hemodynamics and renal function...
  23. ncbi Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study
    Tyree H Kiser
    Department of Clinical Pharmacy, School of Pharmacy, University of Colorado Health Sciences Center, Denver, CO, USA
    Nephrol Dial Transplant 20:1813-20. 2005
    b>Hepatorenal syndrome (HRS) is a severe complication of cirrhosis and is associated with high mortality. Ornipressin and terlipressin are effective in treatment of HRS, but are not available in the USA...
  24. pmc Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics
    Thomas D Boyer
    Dept of Medicine, University of Arizona, College of Medicine, Tucson, AZ, United States
    J Hepatol 55:315-21. 2011
    ..However, only about 1/3 of patients respond to treatment, therefore, predictors of response and survival would help identify the patients most likely to benefit from treatment...
  25. ncbi Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome
    Aleksander Krag
    Department of Gastroenterology, Hvidovre Hospital, Denmark
    Hepatology 46:1863-71. 2007
    ..The vasoconstrictor terlipressin improves renal function in hepatorenal syndrome (HRS)...
  26. doi Recent advances in our understanding of hepatorenal syndrome
    Florence Wong
    Toronto General Hospital, University of Toronto, 200 Elizabeth Street, Toronto, ON M5G 2C4, Canada
    Nat Rev Gastroenterol Hepatol 9:382-91. 2012
    b>Hepatorenal syndrome (HRS) is a serious complication of advanced cirrhosis with ascites. HRS develops as a result of abnormal haemodynamics, leading to splanchnic and systemic vasodilatation, but renal vasoconstriction...
  27. ncbi Serum cystatin C level is a good prognostic marker in patients with cirrhotic ascites and normal serum creatinine levels
    Yeon Seok Seo
    Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea
    Liver Int 29:1521-7. 2009
    ..This study evaluated the clinical significance of CysC in patients with cirrhotic ascites and a normal serum Cr level...
  28. ncbi Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome
    Florence Wong
    Division of Gastroenterology, Department of Medicine, Toronto General Hospital, University of Toronto, Toronto, Canada
    Hepatology 47:160-8. 2008
    Renal vasoconstriction is a key factor in the development of hepatorenal syndrome (HRS) and may be secondary to increased activities of endothelin-1, a potent renal vasoconstrictor...
  29. ncbi Systematic review: renal and other clinically relevant outcomes in hepatorenal syndrome trials
    P Tandon
    Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, AB, Canada
    Aliment Pharmacol Ther 25:1017-28. 2007
    Although reversal of pretransplant renal dysfunction in hepatorenal syndrome reduces post-transplant complications, the overall impact on morbidity and mortality requires clarification.
  30. ncbi The role of duplex-doppler ultrasonography in the diagnosis of renal dysfunction and hepatorenal syndrome in patients with liver cirrhosis
    Snijezana Kastelan
    Department of Gastroenterology, Clinical Hospital Sestre Milosrdnice, Zagreb, Croatia
    Hepatogastroenterology 51:1408-12. 2004
    ..measured by duplex-Doppler ultrasonography for detecting early impairment of renal function in patients with liver cirrhosis and its possible use in detecting a subgroup of patients with a higher risk of developing hepatorenal syndrome.
  31. ncbi [Intrarenal arterial doppler ultrasonography in cirrhotic patients with ascites, with and without hepatorenal syndrome]
    Alberto Bardi
    Centro de Gastroenterología y Unidad de Nefrología, Departamento de Medicina y Servicio de Radiología, Hospital Clinico Universidad de Chile
    Rev Med Chil 130:173-80. 2002
    The pathophysiological hallmark of the hepatorenal syndrome (HRS) is renal vasoconstriction...
  32. doi Hepatorenal syndrome
    Monica Guevara
    Hospital Clinic Barcelona, Liver Unit, IDIBAPS, CIBERHED, Barcelona, Spain
    Expert Opin Pharmacother 12:1405-17. 2011
    ..Renal failure in cirrhosis is a common complication that is associated with poor survival. A rapid diagnosis of the cause of renal failure is mandatory because it is associated with prognosis...
  33. ncbi Hepatorenal syndrome: a dreaded complication of end-stage liver disease
    Andres Cardenas
    Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Boston, MA 02215, USA
    Am J Gastroenterol 100:460-7. 2005
    b>Hepatorenal syndrome is the dreaded complication of end-stage liver disease characterized by functional renal failure due to renal vasoconstriction in the absence of underlying kidney pathology...
  34. ncbi Review article: albumin in the treatment of liver diseases--new features of a classical treatment
    V Arroyo
    Liver Unit, Institute of Digestive Diseases, Hospital Clinic, University of Barcelona, Spain
    Aliment Pharmacol Ther 16:1-5. 2002
    ..have clearly demonstrated its efficacy in the prevention and treatment of circulatory dysfunction and hepatorenal syndrome in patients with cirrhosis...
  35. doi Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome
    Catherine Skagen
    Section of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    J Clin Gastroenterol 43:680-5. 2009
    Few therapeutic modalities exist for the treatment of hepatorenal syndrome (HRS)...
  36. ncbi [Hepatorenal syndrome in patients with liver cirrhosis]
    Stéphane Zaza
    Division des soins intensifs, Departement de Medecine Interne, CHU Vaudois, Rue du Bugnon 11, 1011 Lausanne, Switzerland
    Nephrol Ther 1:174-82. 2005
    b>Hepatorenal syndrome is a particular form of functional renal failure which may develop in patients with liver cirrhosis...
  37. ncbi Hepatorenal syndrome: a review
    Gianni Testino
    Unit of Alcoholic Diseases and Hepatology, Department of Specialistic Medicine, San Martino Hospital, Genova, Italy
    Hepatogastroenterology 57:1279-84. 2010
    b>Hepatorenal Syndrome (HRS) is a serious and life-threatening complication of portal hypertension and end stage liver disease...
  38. ncbi Terlipressin and albumin combination treatment in hepatorenal syndrome
    Ahmet Danalioglu
    Istanbul University, Istanbul Medical Faculty, Gastroenterohepatology Department, Turkey
    Hepatogastroenterology 50:ccciii-cccv. 2003
    b>Hepatorenal syndrome (HRS) is a severe complication of cirrhosis, leading to death in nearly all of cases in the absence of liver transplantation. Several treatments have been attempted as a bridge to liver transplantation...
  39. ncbi Single pass albumin dialysis in hepatorenal syndrome
    Ebadur Rahman
    Department of Medicine, King Khalid University Hospital, Riyadh, Saudi Arabia
    Saudi J Kidney Dis Transpl 19:479-84. 2008
    b>Hepatorenal syndrome (HRS) is the most appalling complication of acute or chronic liver disease with 90% mortality rate. Single pass albumin dialysis (SPAD) can be considered as a noble liver support technique in HRS...
  40. doi Management of refractory ascites and hepatorenal syndrome
    Amy N Sussman
    Department of Medicine, University of Arizona College of Medicine, Tucson, AZ 85724, USA
    Curr Gastroenterol Rep 13:17-25. 2011
    ..Lastly, the development of hepatorenal syndrome indicates the patient's liver disease is advanced, and transplantation again is the best option...
  41. ncbi Type-1 hepatorenal syndrome in patients with alcoholic end stage liver disease listed for liver transplantation: role of transjugular intrahepatic portosystemic stent shunt
    G Testino
    Panminerva Med 49:43-5. 2007
  42. doi Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study
    C Alessandria
    Division of Gastroenterology and Hepatology, San Giovanni Battista Hospital, Turin, Italy
    Dig Liver Dis 41:298-302. 2009
    b>Hepatorenal syndrome is a severe complication of cirrhosis. Treatment with terlipressin has currently the best efficacy pedigree, inducing hepatorenal syndrome reversal in a high proportion of patients...
  43. ncbi Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome
    Søren Møller
    Department of Clinical Physiology 239, Hvidovre Hospital, University of Copenhagen, DK 2650, Hvidovre, Denmark
    Scand J Gastroenterol 40:491-500. 2005
    b>Hepatorenal syndrome (HRS) is a functional and reversible impairment of renal function in patients with severe cirrhosis...
  44. doi Degree of hepatic dysfunction and improvement of renal function predict survival in patients with HRS type I: a retrospective analysis
    Beate Appenrodt
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    Eur J Gastroenterol Hepatol 21:1428-32. 2009
    b>Hepatorenal syndrome (HRS) is a frequent complication of end-stage liver cirrhosis. HRS type I has a very poor prognosis...
  45. ncbi Which patients benefit from hemodialysis therapy in hepatorenal syndrome?
    Oliver Witzke
    Department of Nephrology, University Clinic Essen, Essen, Germany
    J Gastroenterol Hepatol 19:1369-73. 2004
    b>Hepatorenal syndrome (HRS) occurs in patients with advanced liver cirrhosis and has a poor outcome. The aim of the present study was to investigate which patients with HRS are likely to benefit from hemodialysis.
  46. ncbi Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico
    Linda E Muñoz
    Liver Unit, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
    Ann Hepatol 8:207-11. 2009
    Type 1 hepatorenal syndrome (HRS) is a functional renal failure that complicates end-stage cirrhosis. The vasopressin analogue terlipressin has been associated with improved renal function in patients with type 1 HRS.
  47. doi Cystatin C is a good predictor of hepatorenal syndrome and survival in patients with cirrhosis who have normal serum creatinine levels
    Hyung Su Ahn
    Department of Internal Medicine, Chun Hyang University College of Medicine, Bucheon, Korea
    Hepatogastroenterology 59:1168-73. 2012
    ..We evaluated the usefulness of cystatin C as a prognostic marker in patients with liver cirrhosis and normal serum creatinine...
  48. ncbi Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion
    M Guevara
    Liver Unit, Hospital Clinic i Provincial, University of Barcelona, Catalunya, Spain
    Hepatology 27:35-41. 1998
    b>Hepatorenal syndrome is caused by a marked vasoconstriction of the renal circulation...
  49. ncbi Management of refractory ascites and hepatorenal syndrome
    Anuchit Chutaputti
    Section of Digestive and Liver Diseases, Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand
    J Gastroenterol Hepatol 17:456-61. 2002
    Refractory ascites and hepatorenal syndrome (HRS) are the late complications of the terminal stages of cirrhosis...
  50. doi Hepatorenal syndrome: a severe, but treatable, cause of kidney failure in cirrhosis
    Claudia Fagundes
    Liver Unit, Hospital Clinic and University of Barcelona School of Medicine, Institut d Investigacions Biomédiques August Pi Sunyer IDIBAPS, Ciber de Enfermedades Hepáticas y Digestivas CIBERHED, Insituto Reina Sofia de Investigación Nefrológica IRSIN, Barcelona, Catalunya, Spain
    Am J Kidney Dis 59:874-85. 2012
    b>Hepatorenal syndrome (HRS) is a unique type of kidney failure that occurs in advanced cirrhosis...
  51. ncbi Prometheus--a new extracorporeal system for the treatment of liver failure
    Kinan Rifai
    Division of Gastroenterology, Hepatology and Endocrinology, Department of Internal Medicine, Medical School Hannover, Carl Neuberg Strasse 1, 30625 Hannover, Germany
    J Hepatol 39:984-90. 2003
    ..In a simultaneous step, high-flux hemodialysis is performed. We assessed safety, adsorber efficiency and clinical efficacy of the Prometheus system...
  52. ncbi Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome
    Adam G Testro
    Department of Gastroenterology and Liver Transplantation, Austin Hospital, Heidelberg, Victoria, Australia
    J Gastroenterol Hepatol 23:1535-40. 2008
    Studies suggest that terlipressin is effective in the treatment of hepatorenal syndrome (HRS). However, factors predicting response to therapy and the long-term outcome of patients have not been defined.
  53. ncbi New challenge of hepatorenal syndrome: prevention and treatment
    F Wong
    Division of Gastroenterology, Department of Medicine, The Toronto General Hospital, University of Toronto, Ontario, Canada
    Hepatology 34:1242-51. 2001
    b>Hepatorenal syndrome (HRS) remains one of the major therapeutic challenges in hepatology today...
  54. doi Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome
    Aleksander Krag
    Department of Gastroenterology, Hvidovre University Hospital, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
    Adv Ther 25:1105-40. 2008
    ..used in the treatment of patients with cirrhosis and bleeding esophageal varices (BEV) and in patients with hepatorenal syndrome (HRS): two of the most dramatic and feared complications of cirrhosis...
  55. ncbi Terlipressin-induced vasoconstriction reversed with N-acetylcysteine: a case for combined use in hepatorenal syndrome?
    Sambit Sen
    Gastroenterology 123:2160-1. 2002
  56. ncbi Review article: pharmacological treatment of the hepatorenal syndrome in cirrhotic patients
    L Dagher
    Department of Liver Transplantation and Hepatobiliary Medicine, Royal Free Hospital, London, UK
    Aliment Pharmacol Ther 14:515-21. 2000
    ..Where there is no anatomical or pathological cause for the renal failure, it is termed the hepatorenal syndrome. When the hepatorenal syndrome develops, it will only recover when there is some degree of improvement in ..
  57. ncbi Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials
    Fabrizio Fabrizi
    Division of Nephrology and Dialysis, Maggiore Hospital, IRCCS Foundation, Milan Italy
    Int J Artif Organs 32:133-40. 2009
    b>Hepatorenal syndrome (HRS) is a severe complication of end-stage renal disease whose management still constitutes a big challenge. Various approaches have been used for hepatorenal syndrome treatment, including vasoconstrictor therapy...
  58. doi Hepatorenal syndrome
    Deepak Venkat
    Department of Internal Medicine, Ohio State University Medical Center, Columbus, OH 43210, USA
    South Med J 103:654-61. 2010
    Acute kidney injury (AKI) secondary to hepatorenal syndrome (HRS) is an ominous complication of end-stage liver disease (ESLD)...
  59. ncbi Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2
    Carlo Alessandria
    Department of Gastroenterology, San Giovanni Battista Hospital, Torino, Italy
    Eur J Gastroenterol Hepatol 14:1363-8. 2002
    Renal failure secondary to hepatorenal syndrome or to organic renal disease occurs frequently in cirrhotic patients with portal hypertension...
  60. doi Treatment of hepatorenal syndrome
    Tyree H Kiser
    Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, CO 80045, USA
    Pharmacotherapy 29:1196-211. 2009
    b>Hepatorenal syndrome (HRS) is a type of renal failure that occurs in patients with advanced cirrhosis...
  61. doi Outcome of patients with hepatorenal syndrome type 1 after liver transplantation: Hangzhou experience
    Xiao Xu
    Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
    Transplantation 87:1514-9. 2009
    Patients with hepatorenal syndrome (HRS) type 1 have an extremely poor prognosis. Liver transplantation (LT) is the only treatment that can cure terminal stage liver disease and reverse HRS...
  62. doi Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome
    André Nazar
    Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Catalunya, Spain
    Hepatology 51:219-26. 2010
    Terlipressin plus albumin is an effective treatment for type 1 hepatorenal syndrome (HRS), but approximately only half of the patients respond to this therapy...
  63. ncbi Rift Valley fever hepatitis complicated by disseminated intravascular coagulation and hepatorenal syndrome
    Tarig S Al-Khuwaitir
    Department of Medicine, Riyadh Medical Complex, Riyadh, Kingdom of Saudi Arabia
    Saudi Med J 25:528-31. 2004
  64. ncbi Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study
    Tea Restuccia
    Liver Unit, Institute for Digestive Diseases, Hospital Clinic, University of Barcelona, Villarroel 170, Barcelona 08036, Catalunya, Spain
    J Hepatol 40:140-6. 2004
    Pretransplant renal function is the major determinant of survival after liver transplantation (LTx). Patients with hepatorenal syndrome (HRS) have a poor outcome after LTx compared with patients transplanted without HRS.
  65. ncbi Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study
    Gilles Pomier-Layrargues
    Liver Unit, Hopital Saint Luc, Centre Hospitalier de l Universite de Montreal, Montreal, Canada
    Hepatology 38:238-43. 2003
    The hepatorenal syndrome (HRS) is related to vasoconstriction of the renal cortex induced by systemic hypovolemia that follows splanchnic vasodilatation as the primary event in the cascade of hemodynamic changes associated with portal ..
  66. doi Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment
    Florence Wong
    Division of Gastroenterology, Department of Medicine, University of Toronto, 9N 983 Toronto General Hospital, 200 Elizabeth Street, Toronto M5G 2C4, Ontario, Canada
    Gut 59:381-6. 2010
    The pathogenetic mechanism of hepatorenal syndrome (HRS) is paradoxical renal vasoconstriction consequent upon systemic and splanchnic arterial vasodilatation...
  67. ncbi Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials
    Sashidhar V Sagi
    Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA
    J Gastroenterol Hepatol 25:880-5. 2010
    b>Hepatorenal syndrome (HRS) is a serious complication of advanced liver disease and carries a poor prognosis. Recent trials have indicated that terlipressin may be effective in reversing HRS...
  68. doi TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update
    Martin Rossle
    Praxiszentrum, Bertoldstrasse 48, Freiburg, Germany
    Gut 59:988-1000. 2010
    Refractory ascites is a frequent complication of advanced cirrhosis and is associated with hepatorenal syndrome and hepatic hydrothorax...
  69. ncbi Does hepatorenal syndrome affect the result of liver transplantation? Clinical observations
    I Park
    Department of Nephrology, Ajou University School of Medicine, Suwon, Gyeonggi Do, Republic of Korea
    Transplant Proc 42:2563-6. 2010
    b>Hepatorenal syndrome (HRS) is a reversible, functional renal failure that occurs in patients with advanced hepatic failure...
  70. ncbi Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system
    S R Mitzner
    Department of Medicine, University of Rostock, Germany
    Ther Apher 5:417-22. 2001
    Recently, significant improvement of renal function and prolongation of survival were reported in hepatorenal syndrome (HRS) patients treated with the Molecular Adsorbent Recirculating System (MARS)...
  71. doi Accuracy of MELD scores in predicting mortality in decompensated cirrhosis from variceal bleeding, hepatorenal syndrome, alcoholic hepatitis, or acute liver failure as well as mortality after non-transplant surgery or TIPS
    Mohamad R Al Sibae
    Division of Transplantation, Department of Surgery, William Beaumont Hospital, Royal Oak, MI 48073, USA
    Dig Dis Sci 56:977-87. 2011
    ....
  72. ncbi Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study
    J P Mulkay
    Department of Gastroenterology, Hopital Erasme, , Brussels, Belgium
    Acta Gastroenterol Belg 64:15-9. 2001
    BACKGROUND: Hepatorenal syndrome (HRS) is a severe complication of liver cirrhosis. Recently, ornipressin, a potent splanchnic vasoconstrictor, was reported to improve renal function in patients with HRS...
  73. ncbi Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome
    J Salo
    Department of Medicine, Hospital Clinic i Provincial, Barcelona, Spain
    J Hepatol 25:916-23. 1996
    Intravenous ornipressin in cirrhotic patients with hepatorenal syndrome causes marked improvement of systemic hemodynamics and suppression of plasma renin and norepinephrine but only moderate improvement of renal function...
  74. ncbi Circulatory function and hepatorenal syndrome in cirrhosis
    Luis Ruiz-del-Arbol
    Hepatic Hemodynamic Unit, Gastroenterology Department, Hospital Ramon y Cajal, University of Alcala, Ctra de Colmenar Viejo Km 9 1, 28034 Madrid, Spain
    Hepatology 42:439-47. 2005
    The pathogenic mechanism of hepatorenal syndrome is not well established. We investigated the circulatory function in cirrhosis before and after the development of hepatorenal syndrome...
  75. ncbi Hepatorenal syndrome--is it central hypovolemia, a cardiac disease, or part of gradually developing multiorgan dysfunction?
    Kurt Lenz
    Hepatology 42:263-5. 2005
  76. pmc Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis
    Francesco Salerno
    Department of Internal Medicine, Policlinico IRCCS San Donato, University of Milan, Via Morandi, 30, 20097 San Donato MI, Italy
    Gut 56:1310-8. 2007
  77. ncbi [Successful conservative therapy of hepatorenal syndrome with vasopressin-1-receptor antagonist ornipressin]
    V Gulberg
    Medizinische Klinik II, Ludwig Maximilians Universitat, Munchen
    Z Gastroenterol 36:1053-8. 1998
    ..So far, no noninvasive therapy of hepatorenal syndrome has been established...
  78. ncbi Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study
    Rolando Ortega
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, University of Barcelona, Institut d Investigacions Biomédiques August Pi Sunyer IDIBAPS, Catalunya, Spain
    Hepatology 36:941-8. 2002
    Vasopressin analogues associated with albumin improve renal function in hepatorenal syndrome (HRS)...
  79. ncbi Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial
    Prashant Solanki
    Department of Gastroenterology, GB Pant Hospital, New Delhi, India
    J Gastroenterol Hepatol 18:152-6. 2003
    b>Hepatorenal syndrome (HRS) occurs in about 18% of cirrhotic patients with ascites and is characterized by intense renal vasoconstriction, low glomerular filtration rate and preserved tubular function and normal renal histology...
  80. ncbi Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study
    C Alessandria
    Division of Gastroenterology and Hepatology, San Giovanni Battista Hospital, Torino, Italy
    J Hepatol 47:499-505. 2007
    Treatment of hepatorenal syndrome (HRS) is based on vasoconstrictors. Terlipressin is the one with the soundest evidence. Noradrenalin has been suggested as an effective alternative...
  81. ncbi Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management
    Vicente Arroyo
    Liver Unit, Institute of Digestive Diseases, Hospital Clinic, Villarroel, 170, University of Barcelona, 08036 Barcelona, Spain
    J Hepatol 38:S69-89. 2003
  82. ncbi Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis
    Javier Fernandez
    Liver Unit, Hospital Clinic Barcelona, Barcelona, Spain
    Gastroenterology 133:818-24. 2007
    ..Norfloxacin is highly effective in preventing spontaneous bacterial peritonitis recurrence in cirrhosis, but its role in the primary prevention of this complication is uncertain...
  83. pmc Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial
    Andreas Umgelter
    Medizinische Klinik und Poliklinik der Technischen Universität München, Ismaningerstrasse 22, 81675 Munchen, Germany
    Crit Care 12:R4. 2008
    ..This study investigates the short-term effects of paracentesis on haemodynamics and kidney function in volume resuscitated patients with HRS...
  84. doi Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis
    Vanessa Stadlbauer
    Liver Failure Group, Institute of Hepatology, Division of Medicine, University College London, London, England
    Gastroenterology 134:111-9. 2008
    ..is critically dependent on renal perfusion pressure and that this contributes to the development of the hepatorenal syndrome. The aims of the study were to determine the relationship of renal blood flow and renal perfusion pressure ..
  85. ncbi The growing evidence that renal function should be improved in patients with cirrhosis and hepatorenal syndrome before liver transplantation
    Richard Moreau
    J Hepatol 40:159-61. 2004
  86. ncbi Pathogenesis and treatment of hepatorenal syndrome
    Vicente Arroyo
    Liver Unit, Institute of Digestive and Metabolic Diseases, CIBERehd, Hospital Clinic, University of Barcelona, Spain
    Semin Liver Dis 28:81-95. 2008
    b>Hepatorenal syndrome (HRS) is a functional renal failure that frequently develops in patients with advanced cirrhosis and severe impairment in systemic circulatory function...
  87. ncbi Vasopressin analogues in the treatment of hepatorenal syndrome and gastrointestinal haemorrhage
    Klaus D Döhler
    Curatis Pharma GmbH, Karl Wiechert Allee 76, D 30625 Hannover, Germany
    Best Pract Res Clin Anaesthesiol 22:335-50. 2008
    Bleeding of oesophageal varices and hepatorenal syndrome are most dramatic complications in gastroenterology...
  88. pmc Development of hepatorenal syndrome in bile duct ligated rats
    Regina M Pereira
    Departamento de Pediatria, Faculdade de Medicina, Endereco, Avenida Bernardo Monteiro, Minas Gerais 30150 281, Brazil
    World J Gastroenterol 14:4505-11. 2008
    ..To evaluate in bile duct ligated rats whether there were progressive alterations of renal function without changes in histopathology...
  89. ncbi Low-dose vasopressin restores diuresis both in patients with hepatorenal syndrome and in anuric patients with end-stage heart failure
    A Eisenman
    Liver Unit, Department of Internal Medicine B, Rambam Medical Center, Technion Israel Institute of Technology, Haifa, Israel
    J Intern Med 246:183-90. 1999
    ..to confirm earlier reports that low-dose vasopressin (LDVP) analogues promote urine output in patients with hepatorenal syndrome (HRS) and to check whether this mode of therapy could also be effective in renal shutdown due to nonhepatic ..
  90. ncbi Hepatorenal syndrome in patients with cirrhosis
    Richard Moreau
    Laboratoire d Hémodynamique Splanchnique et de Biologie Vasculaire, INSERM U 481, and Service d Hépatologie, Hopital Beaujon, Clichy, France
    J Gastroenterol Hepatol 17:739-47. 2002
    Type 1 hepatorenal syndrome (HRS) is a severe complication of end-stage cirrhosis. Type 1 HRS is an acute functional renal failure (i.e...
  91. ncbi Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome
    Florence Wong
    Division of Gastroenterology, Department of Medicine, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada
    Hepatology 40:55-64. 2004
    b>Hepatorenal syndrome (HRS) is a functional renal disorder complicating decompensated cirrhosis. Treatments to date, except liver transplantation, have been able to improve but not normalize renal function...
  92. ncbi Outpatient management of cirrhosis: a narrative review
    Ronnie E Mathews
    Division of General Internal Medicine, Department of Medicine, University of Alabama at Birmingham, USA
    South Med J 99:600-6. 2006
    ..complications include spontaneous bacterial peritonitis, hepatocellular carcinoma, hepatic encephalopathy, hepatorenal syndrome, and hepatopulmonary syndrome...
  93. pmc Current management of the complications of portal hypertension: variceal bleeding and ascites
    Nina Dib
    Department of Hepato Gastroenterology, University Hospital, and HIFIH Laboratory, Universite d Angers, Angers, France
    CMAJ 174:1433-43. 2006
    ..is sometimes refractory to treatment and is complicated by spontaneous bacterial peritonitis and hepatorenal syndrome. We describe the pathophysiology of portal hypertension and the current management of its complications, ..
  94. ncbi Advances in critical care hepatology
    M L Volk
    Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan 48102 0632, USA
    Minerva Anestesiol 72:269-81. 2006
    ..liver disease is best discussed in terms of the various complications that may ensue such as ascites, hepatorenal syndrome, spontaneous bacterial peritonitis, variceal hemorrhage and hepatic encephalopathy...
  95. ncbi Portal hypertension
    Guadalupe Garcia-Tsao
    Section of Digestive Diseases, Yale University School of Medicine and Connecticut VA, Healthcare System, New Haven, 06510, USA
    Curr Opin Gastroenterol 22:254-62. 2006
    ..Significant advances in the pathophysiology, diagnosis and management of the complications of portal hypertension that have occurred in the last year are reported...
  96. ncbi [Complications of liver cirrhosis. Is it still possible to help these patients?]
    Peter Stiefelhagen
    MMW Fortschr Med 150:12-5. 2008
  97. ncbi [Hepatorenal syndrome]
    Katarzyna Romejko-Ciepielewska
    Katedra i Klinika Chorób Wewnetrznych i Nefrologii AM w Warszawie
    Pol Arch Med Wewn 114:813-8. 2005
  98. doi Fluid retention in cirrhosis: pathophysiology and management
    A Kashani
    Department of Internal Medicine, Division of Gastronterology and Hepatology, University of California, Davis Medical Center, 4150 V Street PSSB 3500, Sacramento, CA 95817, USA
    QJM 101:71-85. 2008
    ..Diagnostic paracentesis and antibiotic therapy plus prophylactic regimen are mandatory. Hepatorenal syndrome is a state of functional renal failure in the setting of low cardiac output and impaired renal perfusion...
  99. ncbi New management options for end-stage chronic liver disease and acute liver failure: potential for pediatric patients
    Dominique Debray
    Paediatric Hepatology Unit, Hôpital Bicêtre Assistance Publique Hôpitaux de Paris, Cedex, France
    Paediatr Drugs 8:1-13. 2006
    ..g. refractory ascites, hepatorenal syndrome, encephalopathy, and cerebral edema) that may be applied to children are reviewed in this article...
  100. ncbi The management and nursing care of cirrhotic ascites
    Suzanne Sargent
    Institute of Liver Studies, King s College Hospital, London
    Br J Nurs 15:212-9. 2006
    ..In recent years, however, there have been several advances in the management of ascites. This article will discuss both the pathophysiology, and the current medical, surgical and nursing management of this condition...
  101. pmc Towards goal-directed therapy of hepatorenal syndrome: we have the tools but we need the trials
    Rajeshwar P Mookerjee
    Liver Failure Group, Institute of Hepatology, 69 75 Chenies Mews, London WC1E 6HX, UK
    Crit Care 12:119. 2008
    Patients with cirrhosis who develop tense ascites and hepatorenal syndrome have a very high mortality and present a management challenge...

Research Grants58

  1. PREDICTING AND IMPROVING OUTCOMES IN ACUTE RENAL FAILURE
    Ravindra Mehta; Fiscal Year: 2001
    ..It is anticipated (by the applicants) that information gained from this study, being largely observational, will be used to rationally design intervention strategies in future years. ..
  2. STRUCTURAL IDENTIFICATION OF PROSTAGLANDIN CONJUGATES
    L Roberts; Fiscal Year: 1993
    ..that overproduction of isoprostanes and oxidant stress may play a fundamental role in the development of hepatorenal syndrome in humans...
  3. Liver Derived Microparticles In Cirhossis Pathogenesis
    RAFAL WITEK; Fiscal Year: 2009
    ..including cutaneous spider telangectases, cachexia, increased intestinal permeability, ascites and the hepatorenal syndrome, the portopulmonary syndrome, and hepatic encephalopathy...
  4. Regulation of Renal Cortical Adenosine Levels
    Edwin Jackson; Fiscal Year: 2005
    ..identify a novel pathway by which the pancreas and liver regulate renal cortical interstitial levels of adenosine and may reveal important mechanistic insights into diseases such as the hepatorenal syndrome and the metabolic syndrome X.
  5. Regulation of Renal Cortical Adenosine Levels
    Edwin Jackson; Fiscal Year: 2007
    ..identify a novel pathway by which the pancreas and liver regulate renal cortical interstitial levels of adenosine and may reveal important mechanistic insights into diseases such as the hepatorenal syndrome and the metabolic syndrome X.
  6. Identifying acute tubular necrosis in cirrhosis patients with renal dysfunction
    Chirag Parikh; Fiscal Year: 2009
    ..In these cases, the main differential is between type 1 hepatorenal syndrome (HRS) and acute tubular necrosis (ATN)...
  7. Regulation of Renal Cortical Adenosine Levels
    Edwin Jackson; Fiscal Year: 2009
    ..identify a novel pathway by which the pancreas and liver regulate renal cortical interstitial levels of adenosine and may reveal important mechanistic insights into diseases such as the hepatorenal syndrome and the metabolic syndrome X.
  8. Regulation of Renal Cortical Adenosine Levels
    Edwin Jackson; Fiscal Year: 2006
    ..identify a novel pathway by which the pancreas and liver regulate renal cortical interstitial levels of adenosine and may reveal important mechanistic insights into diseases such as the hepatorenal syndrome and the metabolic syndrome X.
  9. Identifying acute tubular necrosis in cirrhosis patients with renal dysfunction
    Chirag R Parikh; Fiscal Year: 2010
    ..In these cases, the main differential is between type 1 hepatorenal syndrome (HRS) and acute tubular necrosis (ATN)...
  10. Novel therapies in alcoholic hepatitis University of Louisville
    Craig J McClain; Fiscal Year: 2012
    ..Studies on pentoxifylline in AH are limited, and efficacy appears highest in preventing/treating the hepatorenal syndrome. Thus, new therapies as well as a better understanding of mechanisms/biomarkers for severity of disease and ..
  11. IMMUNOASSAY FOR A NON-ENZYMATIC ARACHIDONATE DERIVATIVE
    KRISHNAMOORTHY SANKARAN; Fiscal Year: 1993
    ..significant diagnostic potential for the assessment of oxidative stress and in specific disorders such as hepatorenal syndrome, rheumatoid arthritis, and carcinogenesis. Isoprostanes have thus far been detected by mass spectrometry...
  12. STRUCTURAL IDENTIFICATION OF PROSTAGLANDIN CONJUGATES
    L Roberts; Fiscal Year: 2000
    ..The role of free radicals and IsoP's in mediating the renal dysfunction in an animal model of the hepatorenal syndrome will also be explored...
  13. PROSTAGLANDINS AND THROMBOXANES IN LIVER FAILURE
    Robert Zipser; Fiscal Year: 1980
    ..The sequential pattern of prostaglandin excretion during the progression of hepatorenal syndrome will be analyzed...
  14. STRUCTURAL IDENTIFICATION OF PROSTAGLANDIN CONJUGATES
    L Roberts; Fiscal Year: 1999
    ..The role of free radicals and IsoP's in mediating the renal dysfunction in an animal model of the hepatorenal syndrome will also be explored...
  15. Outpatient treatment for portal hypertension
    Elijah M Bolotin; Fiscal Year: 2010
    ..to prevent the development of life-threatening consequences, including bleeding esophageal varices and hepatorenal syndrome (HRS), pharmacological treatment options are severely limited...
  16. Terlipressin in Hepatorenal Syndrome Type 1
    PETER TEUBER; Fiscal Year: 2005
    ..Randomized, Placebo-Controlled, Multicenter Phase 3 Study of Intravenous Terlipressin in Patients with Hepatorenal Syndrome (HRS) Type 1...
  17. STRUCTURAL IDENTIFICATION OF PROSTAGLANDIN CONJUGATES
    L Jackson Roberts; Fiscal Year: 2010
    ..Finally, we will test the hypothesis that free radicals and IsoPs play an important role in the renal failure that ensues in glactosamine treated rats, an animal model of the hepatorenal syndrome.
  18. STRUCTURAL IDENTIFICATION OF PROSTAGLANDIN CONJUGATES
    L Roberts; Fiscal Year: 2007
    ..Finally, we will test the hypothesis that free radicals and IsoPs play an important role in the renal failure that ensues in glactosamine treated rats, an animal model of the hepatorenal syndrome.
  19. STRUCTURAL IDENTIFICATION OF PROSTAGLANDIN CONJUGATES
    L Roberts; Fiscal Year: 2009
    ..Finally, we will test the hypothesis that free radicals and IsoPs play an important role in the renal failure that ensues in glactosamine treated rats, an animal model of the hepatorenal syndrome.
  20. GENERAL CLINICAL RESEARCH CENTER
    Arthur Richardson; Fiscal Year: 1980
    ..6. Liver Disease: Hepatorenal syndrome; gastroesophageal varices; treatment of alcoholic hepatitis; surgery for portal hypertension and ..
  21. GENERAL CLINICAL RESEARCH CENTER
    Stuart Bondurant; Fiscal Year: 1990
    ..6. Liver Disease: Hepatorenal syndrome; gastroesophageal varices; treatment of alcoholic hepatitis; surgery for portal hypertension and ..
  22. GENERAL CLINICAL RESEARCH CENTER
    Philip Pizzo; Fiscal Year: 2006
    ..Sikic). (6) Clinical Experiment of Helicobacter PyloriTransmission (Julie Parsonnet). (7) Pathophysiology of Hepatorenal Syndrome (Bryan D. Myers). (8) Gene Therapy for Hemophilia (Mark Kay and Bertil Glader).
  23. STRUCTURAL IDENTIFICATION OF PROSTAGLANDIN CONJUGATES
    L Roberts; Fiscal Year: 2005
    ..Finally, we will test the hypothesis that free radicals and IsoPs play an important role in the renal failure that ensues in glactosamine treated rats, an animal model of the hepatorenal syndrome.
  24. RENAL KALLIKREIN IN KIDNEY FUNCTION AND DISEASE
    Norman Levinsky; Fiscal Year: 1980
    ..Clinical studies of kallikrein in kidney disease, hepatorenal syndrome, Bartter's syndrome and other relevant human diseases, will be performed.
  25. STRUCTURAL IDENTIFICATION OF PROSTAGLANDIN CONJUGATES
    L Roberts; Fiscal Year: 2004
    ..Finally, we will test the hypothesis that free radicals and IsoPs play an important role in the renal failure that ensues in glactosamine treated rats, an animal model of the hepatorenal syndrome.
  26. STRUCTURAL IDENTIFICATION OF PROSTAGLANDIN CONJUGATES
    L Roberts; Fiscal Year: 2003
    ..Finally, we will test the hypothesis that free radicals and IsoPs play an important role in the renal failure that ensues in glactosamine treated rats, an animal model of the hepatorenal syndrome.
  27. STRUCTURAL IDENTIFICATION OF PROSTAGLANDIN CONJUGATES
    L Roberts; Fiscal Year: 2002
    ..Finally, we will test the hypothesis that free radicals and IsoPs play an important role in the renal failure that ensues in glactosamine treated rats, an animal model of the hepatorenal syndrome.
  28. STRUCTURAL IDENTIFICATION OF PROSTAGLANDIN CONJUGATES
    L Roberts; Fiscal Year: 2001
    ..Finally, we will test the hypothesis that free radicals and IsoPs play an important role in the renal failure that ensues in glactosamine treated rats, an animal model of the hepatorenal syndrome.
  29. CIRRHOSIS AND ITS COMPLICATIONS
    Guadalupe Garcia Tsao; Fiscal Year: 2007
    ..Renewal of the award will allow Dr. Garcia-Tsao to maintain both POR and her mentoring endeavors to their fullest extent so she can continue to make significant contributions in the field of chronic liver disease and its complications. ..
  30. CIRRHOSIS AND ITS COMPLICATIONS
    Guadalupe Garcia Tsao; Fiscal Year: 2008
    ..Renewal of the award will allow Dr. Garcia-Tsao to maintain both POR and her mentoring endeavors to their fullest extent so she can continue to make significant contributions in the field of chronic liver disease and its complications. ..
  31. Training Grant in Digestive Diseases and Liver Diseases
    Arun Sanyal; Fiscal Year: 2007
    ..The need for research training, the strong record and continued research strengths of this program for the basis for this application for renewal of this T-32 Training Grant. ..
  32. Biliary Microlithiasis in Alcohol Induced Pancreatitis
    Arun Sanyal; Fiscal Year: 2007
    ..The long-term goal is to use data from this R21 proposal to develop a RO1 proposal about a large scale phase III clinical trial of UDCA for alcohol-induced pancreatitis. [unreadable] [unreadable] [unreadable]..
  33. FACTORS IN THE PREVENTION OF TOXIC LIVER INJURY
    Thomas Boyer; Fiscal Year: 2008
    ..The studies will clarify why expression of certain proteins fall during the acute phase response. ..
  34. Studies of Mechanisms and Treatment of Liver Diseases
    Arun Sanyal; Fiscal Year: 2007
    ..Much progress has been made and supports the hypothesis. The institutional environment and facilities/resources are excellent for career development in academic medicine. ..
  35. FACTORS IN THE PREVENTION OF TOXIC LIVER INJURY
    Thomas Boyer; Fiscal Year: 2001
    ..How phenobarbital selectively stabilizes mRNA in perivenous hepatocytes will be examined further. ..
  36. FACTORS IN THE PREVENTION OF TOXIC LIVER INJURY
    Thomas Boyer; Fiscal Year: 2002
    ..How phenobarbital selectively stabilizes mRNA in perivenous hepatocytes will be examined further. ..
  37. FACTORS IN THE PREVENTION OF TOXIC LIVER INJURY
    Thomas Boyer; Fiscal Year: 2003
    ..How phenobarbital selectively stabilizes mRNA in perivenous hepatocytes will be examined further. ..
  38. FACTORS IN THE PREVENTION OF TOXIC LIVER INJURY
    Thomas Boyer; Fiscal Year: 2007
    ..The studies will clarify why expression of certain proteins fall during the acute phase response. ..
  39. FACTORS IN THE PREVENTION OF TOXIC LIVER INJURY
    Thomas Boyer; Fiscal Year: 2006
    ..The studies will clarify why expression of certain proteins fall during the acute phase response. ..
  40. CLINICAL STUDIES OF NONALCOHOLIC STEATOHEPATITIS
    Arun Sanyal; Fiscal Year: 2007
    ..A prospective, randomized short-term ( 1 year duration) clinical trial to test this hypothesis is proposed. The primary endpoint is the necro-inflammatory grade. Both studies will require participation of the network. ..
  41. Digoxin Chiral Isolates as Improved Pharmaceuticals
    John Somberg; Fiscal Year: 2005
    ..The advantage would be a treatment for AF that did not cause cardiac augmentation and vasoconstriction or a treatment for CHF that does not cause heart rate slowing or conduction disturbances. ..
  42. Angiotensin Metabolite Formation by Podocytes: Implications in Glomerular Injury
    JUAN CARLOS VELEZ; Fiscal Year: 2008
    ..Better understanding of the mechanisms of in the kidney should lead to therapies that can directly target. These therapies would improve both quality and length of life of affected individuals. ..
  43. Pheresis Treatment of Bioterrorism-Induced Sepsis
    Stephen Ash; Fiscal Year: 2005
    ..The safety systems of the existing PF system will be modified to meet the needs of the stand-alone system. Finally, an animal model of sepsis will be used to check efficacy and safety of the entire system. ..
  44. PREDICTING AND IMPROVING OUTCOMES IN ACUTE RENAL FAILURE
    Ravindra Mehta; Fiscal Year: 2000
    ..It is anticipated (by the applicants) that information gained from this study, being largely observational, will be used to rationally design intervention strategies in future years. ..
  45. CLINICAL RESEARCH ENHANCEMENT FROM SUPPLEMENTAL TRAINING
    Ravindra Mehta; Fiscal Year: 2007
    ..IOur goal is to ensure that scholars emerging from this program will have the fundamental skills Inecessary for independent clinical research. ..
  46. MethLock vs. heparin as dialysis catheter lock
    Stephen Ash; Fiscal Year: 2007
    ..In Phase II we will implement the protocol in a number of dialysis centers and complete the study as originally proposed or as modified after Phase I. ..
  47. CLINICAL OUTCOMES IN ELDERLY HIV PATIENTS
    Kelly Gebo; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  48. CLINICAL OUTCOMES IN ELDERLY HIV PATIENTS
    Kelly Gebo; Fiscal Year: 2007
    ..abstract_text> ..
  49. CLINICAL RESEARCH ENHANCEMENT FROM SUPPLEMENTAL TRAINING
    Ravindra Mehta; Fiscal Year: 2008
    ..IOur goal is to ensure that scholars emerging from this program will have the fundamental skills Inecessary for independent clinical research. ..
  50. IMPROVING HEALTH CARE UTILIZATION IN HIV+ DRUG USERS
    Kelly Gebo; Fiscal Year: 2005
    ..Gebo the skills she needs to develop into an independent clinician researcher in HIV epidemiologic and health services research. ..
  51. MethLock vs. heparin as dialysis catheter lock
    Stephen Ash; Fiscal Year: 2008
    ..In Phase II we will implement the protocol in a number of dialysis centers and complete the study as originally proposed or as modified after Phase I. ..
  52. PREDICTING AND IMPROVING OUTCOMES IN ACUTE RENAL FAILURE
    Ravindra Mehta; Fiscal Year: 1999
    ..It is anticipated (by the applicants) that information gained from this study, being largely observational, will be used to rationally design intervention strategies in future years. ..